## INFORMATION DISCLOSURE STATEMENT

Cipollone et al.

App. No

10/567,486

Filed

February 6, 2006

For

METHOD AND KIT FOR ASSESSING

THE RISK OF CARDIOVASCULAR

**PATHOLOGIES WITH** 

ATHEROMATOUS ETIOLOGY

Examiner

Unknown

Art Unit

1645

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 6 references to be considered by the Examiner. Also enclosed are 6 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Outstern 12, 2006

By:

Marina L. Gordey

Registration No. 52,950

Agent of Récord

Customer No. 20,995

(805) 547-5580

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE		Application No.	10/567,486
		Filing Date	February 6, 2006
		First Named Inventor	Cipollone, Francesco
		Art Unit	1645
(Multiple	sheets used when necessary)	Examiner	Unknown
OCT 16 2006	SHEET 1 OF 1	Attorney Docket No.	NOTAR9.001APC
A (2)			

A STATE OF THE STA	245	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
			-			
		<u>-</u>				

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	-					

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	. 1	CHEN, Y. et al. (2003) "Genomic structure and mutational analysis of the human KIF1B $\alpha$ gene located at 1p36.2 in neuroblastoma" <i>International Journal of Oncology</i> 23:737-744.	
	2	PAPAFILI, A. et al. (2002) "Common promoter variant in cyclooxygenase-2 represses gene expression" Arterioscler. Thromb. Vasc. Biol. 22:1631-1636.	
	3	CIPOLLONE, F. et al. (2002) "Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?" <i>Arterioscler. Thromb. Vasc. Biol.</i> 22:1516-1518.	
	4	CIPOLLONE, F. et al. (2001) "Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin e synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E <sub>2</sub> -dependent plaque instability" <i>Circulation</i> 104:921-927.	
	5	CIPOLLONE, F. et al. (2003) "Suppression of the functionally coupled cyclooxygenase-2/prostaglandin e synthase as a basis of simvastatin-dependent plaque stabilization in humans" <i>Circulation</i> 107:1479-1485.	
	6	CIPOLLONE, F et al. (2004) "A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke" <i>JAMA</i> 291:2221-2228.	

2992212:vr100506

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conform in conformance and not considered. Include copy of this form with next communication.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.